Centre for Oncology and Regulatory Research, Biologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, Canada.
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Emerg Microbes Infect. 2023 Dec;12(1):2192821. doi: 10.1080/22221751.2023.2192821.
Influenza and Respiratory Syncytial virus (RSV) infections together contribute significantly to the burden of acute lower respiratory tract infections. Despite the disease burden, no approved RSV vaccine is available. While approved vaccines are available for influenza, seasonal vaccination is required to maintain protection. In addition to both being respiratory viruses, they follow a common seasonality, which warrants the necessity for a concerted vaccination approach. Here, we designed bivalent vaccines by utilizing highly conserved sequences, targeting both influenza A and RSV, as either a chimeric antigen or individual antigens separated by a ribosome skipping sequence. These vaccines were found to be effective in protecting the animals from challenge by either virus, with mechanisms of protection being substantially interrogated in this communication.
流感和呼吸道合胞病毒(RSV)感染共同导致急性下呼吸道感染负担沉重。尽管疾病负担沉重,但目前尚无批准的 RSV 疫苗。虽然有针对流感的批准疫苗,但为了保持保护作用,需要进行季节性疫苗接种。除了都是呼吸道病毒外,它们还具有共同的季节性,这就需要采取协调一致的疫苗接种方法。在这里,我们利用高度保守的序列设计了二价疫苗,针对流感 A 和 RSV,作为嵌合抗原或通过核糖体跳跃序列分离的单个抗原。这些疫苗被发现能有效保护动物免受两种病毒的攻击,在本研究中对保护机制进行了深入研究。